Allegra Generic Launch Prompts Injunction Request

Law360, New York (September 21, 2005, 12:00 AM EDT) -- In an escalation of the patent war over Allegra, a partner of Sanofi Aventis has requested an injunction to prevent rivals from making a generic version of the allergy drug prior to the lawsuit’s conclusion.

In March 2004, Albany Molecular Research Inc. (AMRI) filed lawsuits against Barr Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. in U.S. District Court for New Jersey. The suit pertains to AMRI’s patents for fexofenadine, the active ingredient in Allegra.

AMRI’s patents are licensed to Aventis Pharmaceuticals Inc., part of the French...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.